NO960380L - Middel til behandling av neurosykdommer - Google Patents
Middel til behandling av neurosykdommerInfo
- Publication number
- NO960380L NO960380L NO960380A NO960380A NO960380L NO 960380 L NO960380 L NO 960380L NO 960380 A NO960380 A NO 960380A NO 960380 A NO960380 A NO 960380A NO 960380 L NO960380 L NO 960380L
- Authority
- NO
- Norway
- Prior art keywords
- peripheral
- treatment
- alkyl
- neurological diseases
- nervous
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 210000003050 axon Anatomy 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 150000002339 glycosphingolipids Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Surgical Instruments (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22051893 | 1993-08-13 | ||
| PCT/JP1994/001342 WO1995005177A1 (en) | 1993-08-13 | 1994-08-12 | Remedy for nervous diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO960380D0 NO960380D0 (no) | 1996-01-30 |
| NO960380L true NO960380L (no) | 1996-03-14 |
Family
ID=16752277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO960380A NO960380L (no) | 1993-08-13 | 1996-01-30 | Middel til behandling av neurosykdommer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5707649A (de) |
| EP (1) | EP0720852B1 (de) |
| JP (1) | JP3778926B2 (de) |
| KR (1) | KR960703598A (de) |
| CN (1) | CN1128951A (de) |
| AT (1) | ATE197672T1 (de) |
| AU (1) | AU676361B2 (de) |
| DE (1) | DE69426331T2 (de) |
| HU (1) | HUT73527A (de) |
| NO (1) | NO960380L (de) |
| NZ (1) | NZ269847A (de) |
| WO (1) | WO1995005177A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707649A (en) * | 1993-08-13 | 1998-01-13 | Seikagaku Corporation | Agent for treating neuronal diseases |
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| US5872101A (en) * | 1995-01-06 | 1999-02-16 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
| NO965193L (no) * | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| US6440455B1 (en) * | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
| US6723838B1 (en) | 1998-04-22 | 2004-04-20 | Johns Hopkins University | Signal transducing synaptic molecules and uses thereof |
| ATE409486T1 (de) | 1998-06-29 | 2008-10-15 | Children S Hospital Los Angele | Behandlung hyperproliferativer erkrankungen |
| US6368831B1 (en) | 1998-06-29 | 2002-04-09 | Childrens Hospital Los Angeles | Treatment of hyperproliferative disorders |
| ES2285852T3 (es) * | 1998-07-27 | 2007-11-16 | Johns Hopkins University | Compuestos de diamino-propanol para el tratamiento de la isquemia. |
| US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| EP1384719A1 (de) * | 1999-07-09 | 2004-01-28 | The Regents of The University of Michigan | Inhibitoren des Glykosylzeramidsynthase-Enzyms für die Behandlung von Krebs, Sphingolipidosis und mikrobiellen Infektionen |
| JP5009459B2 (ja) * | 1999-12-06 | 2012-08-22 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| US6407064B2 (en) * | 1999-12-06 | 2002-06-18 | Seikagaku Corporation | Aminoalcohol derivative and medicament comprising the same |
| US20100261159A1 (en) * | 2000-10-10 | 2010-10-14 | Robert Hess | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
| CA2434028C (en) * | 2001-01-10 | 2010-11-09 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| JP3742602B2 (ja) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素ｑの安定な溶液 |
| EP2266968B1 (de) | 2001-07-16 | 2013-01-09 | Genzyme Corporation | Synthese von UDP-Glukose: N-Acetylsphingosin Glikosyltransferase Inhibitoren |
| US6916802B2 (en) * | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| US20060217560A1 (en) * | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US7834147B2 (en) * | 2003-04-28 | 2010-11-16 | Childrens Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
| DE10352449A1 (de) * | 2003-11-07 | 2005-06-16 | Ruprecht-Karls-Universität Heidelberg | Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer |
| DE10352450A1 (de) * | 2003-11-07 | 2005-06-23 | Ruprecht-Karls-Universität Heidelberg | Neues Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer |
| US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| US20090111812A1 (en) * | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| CA2586761A1 (en) * | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
| CN101151248B (zh) | 2005-01-26 | 2012-06-20 | 阿勒根公司 | 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物 |
| WO2006095798A1 (ja) * | 2005-03-09 | 2006-09-14 | Sunstar Inc. | フィトステロールを含んだリポソームを含有する抗癌用経口組成物、該リポソームによる癌の予防又は治療 |
| EP2020988B1 (de) * | 2006-04-28 | 2017-08-16 | Children's Hospital Medical Center | Zusammensetzungen mit fusogenen proteinen oder polypeptiden aus prosaposin zur anwendung auf transmembrane wirkstofffreisetzungssysteme |
| EP2032134B1 (de) * | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese |
| WO2008011487A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain |
| WO2008011483A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
| WO2008109287A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| US8304447B2 (en) | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| KR20160085917A (ko) | 2007-10-05 | 2016-07-18 | 젠자임 코포레이션 | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 |
| WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| WO2010087313A1 (ja) * | 2009-01-29 | 2010-08-05 | 株式会社林原生物化学研究所 | 神経突起伸展促進剤 |
| JP2013510878A (ja) * | 2009-11-12 | 2013-03-28 | テキサス テック ユニバーシティー | 高増殖性障害を処置する組成物および方法 |
| PL3133070T3 (pl) | 2009-11-27 | 2020-01-31 | Genzyme Corporation | Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta |
| WO2011099980A1 (en) | 2010-02-12 | 2011-08-18 | The Johns Hopkins University | Use of the lactosylceramide synthase isoform b1, 4galt-v as a biomarker for cancer |
| US10202340B2 (en) | 2015-02-02 | 2019-02-12 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| EP3501495A1 (de) * | 2017-12-21 | 2019-06-26 | InnoMedica Holding AG | Liposomen mit sphingomyelin |
| JP7698320B2 (ja) | 2019-10-23 | 2025-06-25 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法 |
| WO2021221953A1 (en) | 2020-04-28 | 2021-11-04 | The Regents Of The University Of Michigan | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963297A (en) * | 1987-12-22 | 1990-10-16 | The Liposome Company, Inc. | Spontaneous vesticulation of multilamellar liposomes |
| US5041441A (en) * | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| US5707649A (en) * | 1993-08-13 | 1998-01-13 | Seikagaku Corporation | Agent for treating neuronal diseases |
-
1994
- 1994-08-12 US US08/464,683 patent/US5707649A/en not_active Expired - Lifetime
- 1994-08-12 HU HU9600278A patent/HUT73527A/hu unknown
- 1994-08-12 DE DE69426331T patent/DE69426331T2/de not_active Expired - Lifetime
- 1994-08-12 AT AT94922369T patent/ATE197672T1/de not_active IP Right Cessation
- 1994-08-12 WO PCT/JP1994/001342 patent/WO1995005177A1/ja not_active Ceased
- 1994-08-12 NZ NZ269847A patent/NZ269847A/en unknown
- 1994-08-12 EP EP94922369A patent/EP0720852B1/de not_active Expired - Lifetime
- 1994-08-12 KR KR1019960700688A patent/KR960703598A/ko not_active Withdrawn
- 1994-08-12 JP JP50686095A patent/JP3778926B2/ja not_active Expired - Lifetime
- 1994-08-12 CN CN94193077A patent/CN1128951A/zh active Pending
- 1994-08-12 AU AU73506/94A patent/AU676361B2/en not_active Expired
-
1995
- 1995-06-06 US US08/466,243 patent/US5849326A/en not_active Expired - Lifetime
-
1996
- 1996-01-30 NO NO960380A patent/NO960380L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR960703598A (ko) | 1996-08-31 |
| CN1128951A (zh) | 1996-08-14 |
| HU9600278D0 (en) | 1996-04-29 |
| NO960380D0 (no) | 1996-01-30 |
| ATE197672T1 (de) | 2000-12-15 |
| EP0720852A1 (de) | 1996-07-10 |
| AU676361B2 (en) | 1997-03-06 |
| EP0720852A4 (de) | 1997-07-23 |
| EP0720852B1 (de) | 2000-11-22 |
| WO1995005177A1 (en) | 1995-02-23 |
| AU7350694A (en) | 1995-03-14 |
| US5707649A (en) | 1998-01-13 |
| DE69426331T2 (de) | 2001-06-21 |
| NZ269847A (en) | 1996-11-26 |
| HUT73527A (en) | 1996-08-28 |
| DE69426331D1 (de) | 2000-12-28 |
| US5849326A (en) | 1998-12-15 |
| JP3778926B2 (ja) | 2006-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO960380D0 (no) | Middel til behandling av neurosykdommer | |
| FI935529A0 (fi) | Aminometylensubstituerade icke-aromatiska heterocykliska foereningar | |
| HU9603433D0 (en) | Novel 4-6-diaryl-pyrimidine-derivatives and salts thereof | |
| RU2203274C2 (ru) | Спироциклические ингибиторы металлопротеаз | |
| DE3263734D1 (en) | Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (z), their preparation and their use as medicines in the treatment of disorders of the central nervous system | |
| ES2106573T3 (es) | Composicion oftalmica que contiene un derivado de 1,5-benzoxatiepina para tratar glaucoma. | |
| FI893751A0 (fi) | Kemiska foereningar. | |
| DE68914292D1 (de) | Zusammensetzung zur Behandlung von ischämischen Störungen in Organen. | |
| DE69008142D1 (de) | 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes. | |
| DE69326395D1 (de) | Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms | |
| NO944915D0 (no) | Öking av trambomodulinekspresjon | |
| NO943895D0 (no) | Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter | |
| ATE284684T1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
| EP0838220A4 (de) | Arzneimittel zur heilung von gehirnerkrankungen | |
| RU94045256A (ru) | Применение бензо[g]хинолинов | |
| ATE63541T1 (de) | N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel. | |
| DK74189A (da) | Laegemiddel til behandling af mavesaar | |
| HUT72441A (en) | Pharmaceutical compositions comprising bicycloheptane derivative and process for producing them | |
| ATE153340T1 (de) | Cyathane derivate und diese enthaltende nervenwachstumsfaktor produktion stimulatoren und antimikrobielle mittel | |
| DK0551844T3 (da) | Svovlholdige galdesyrederivater | |
| DE69827706D1 (de) | 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems | |
| RU96105023A (ru) | Агент для лечения нейрональных заболеваний |